• 1
    Clark, B. F. ( 1967) A prerequisite stage in the initiation of polypeptide chains. J. Mol. Biol. 28, 167169.
  • 2
    Clark, B. F. andMarcker, K. A. ( 1966) N-formyl-methionyl-sigma-ribonucleic acid and chain initiation in protein biosynthesis. Polypeptide synthesis directed by a bacteriophage ribonucleic acid in a cell-free system. Nature 211, 378380.
  • 3
    Clark, B. F. andMarcker, K. A. ( 1968) How proteins start. Sci. Am. 218, 3642.
  • 4
    Clark, F. C. andMarcker, K. A. ( 1965) Coding response of N-fromyl-methionyl-sRNA to UUG. Nature 207, 10381039.
  • 5
    Clark, B. F.,Dube, S. K., andMarcker, K. A. ( 1968) Specific codon-anticodon interaction of an initiator-tRNA fragment. Nature 219, 484485.
  • 6
    McLaughlin-Drubin, M. E. andMunger, K. ( 2008) Viruses associated with human cancer. Biochim. Biophys. Acta. 1782, 127150.
  • 7
    Doorbar, J. ( 2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond) 110, 525541.
  • 8
    Woodworth, C. D.,Cheng, S.,Simpson, S.,Hamacher, L.,Chow, L. T.,Broker, T. R., andDiPaolo, J. A. ( 1992) Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 7, 619626.
  • 9
    Scheffner, M.,Werness, B. A.,Huibregtse, J. M.,Levine, A. J., andHowley, P. M. ( 1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 11291136.
  • 10
    von Knebel Doeberitz, M.,Rittmuller, C.,Aengeneyndt, F.,Jansen-Durr, P., andSpitkovsky, D. ( 1994) Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J. Virol. 68, 28112821.
  • 11
    Hafner, N.,Driesch, C.,Gajda, M.,Jansen, L.,Kirchmayr, R.,Runnebaum, I. B., andDurst, M. ( 2008) Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27, 16101617.
  • 12
    Middleton, K.,Peh, W.,Southern, S.,Griffin, H.,Sotlar, K.,Nakahara, T.,El-Sherif, A.,Morris, L.,Seth, R.,Hibma, M., Jenkins, D., Lambert, P., Coleman, N., and Doorbar, J. ( 2003) Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 77, 1018610201.
  • 13
    Branca, M.,Giorgi, C.,Ciotti, M.,Santini, D.,Di Bonito, L.,Costa, S.,Benedetto, A.,Bonifacio, D.,Di Bonito, P.,Paba, P., Accardi, L., Mariani, L., Syrjanen, S., Favalli, C., and Syrjanen, K. ( 2006) Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Eur. J. Gynaecol. Oncol. 27, 215223.
  • 14
    Lichtig, H.,Gilboa, D. A.,Jackman, A.,Gonen, P.,Levav-Cohen, Y.,Haupt, Y., andSherman, L. ( 2010) HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 396, 4758.
  • 15
    Kim, S. H.,Kim, K. S.,Lee, E. J.,Kim, M. O.,Park, J. H.,Cho, K. I.,Imakawa, K.,Hyun, B. H.,Chang, K. T.,Lee, H. T., and Ryoo, Z.Y. ( 2004) Human keratin 14 driven HPV 16 E6/E7 transgenic mice exhibit hyperkeratinosis. Life Sci. 75, 30353042.
  • 16
    Brake, T. andLambert, P. F. ( 2005) Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc. Natl. Acad. Sci. USA 102, 24902495.
  • 17
    Shai, A.,Pitot, H. C., andLambert, P. F. ( 2008) p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res. 68, 26222631.
  • 18
    Chung, S. H.,Wiedmeyer, K.,Shai, A.,Korach, K. S., andLambert, P.F. ( 2008) Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 68, 99289934.
  • 19
    Matsha, T.,Erasmus, R.,Kafuko, A. B.,Mugwanya, D.,Stepien, A., andParker, M. I. ( 2002) Human papillomavirus associated with oesophageal cancer. J. Clin. Pathol. 55, 587590.
  • 20
    Hendricks, D. andParker, M. I. ( 2002) Oesophageal cancer in Africa. IUBMB Life 53, 263268.
  • 21
    Hawley-Nelson, P.,Vousden, K. H.,Hubbert, N. L.,Lowy, D. R., andSchiller, J. T. ( 1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8, 39053910.
  • 22
    Choo, K. B.,Pan, C. C., andHan, S. H. ( 1987) Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161, 259261.
  • 23
    Choo, K. B.,Pan, C. C.,Liu, M. S.,Ng, H. T.,Chen, C. P.,Lee, Y. N.,Chao, C. F.,Meng, C. L.,Yeh, M. Y., andHan, S. H. ( 1987) Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 21, 101107.
  • 24
    Kirshner, J. R.,Staskus, K.,Haase, A.,Lagunoff, M., andGanem, D. ( 1999) Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J. Virol. 73, 60066014.
  • 25
    Sodhi, A.,Montaner, S.,Patel, V.,Zohar, M.,Bais, C.,Mesri, E.A., andGutkind, J. S. ( 2000) The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60, 48734880.
  • 26
    Montaner, S.,Sodhi, A.,Molinolo, A.,Bugge, T. H.,Sawai, E. T.,He, Y.,Li, Y.,Ray, P. E., andGutkind, J. S. ( 2003) Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 2336.
  • 27
    Guasparri, I.,Keller, S. A., andCesarman, E. ( 2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199, 9931003.
  • 28
    Epstein, M. A. ( 2001) Reflections on Epstein-Barr virus: some recently resolved old uncertainties. J. Infect. 43, 111115.
  • 29
    Young, L. S. andMurray, P. G. ( 2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22, 51085121.
  • 30
    Matsuoka, M. ( 2003) Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 22, 51315140.
  • 31
    Felber, B. K.,Paskalis, H.,Kleinman-Ewing, C.,Wong-Staal, F., andPavlakis, G. N. ( 1985) The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 229, 675679.
  • 32
    Terradillos, O.,Billet, O.,Renard, C. A.,Levy, R.,Molina, T.,Briand, P., andBuendia, M. A. ( 1997) The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14, 395404.
  • 33
    McGivern, D. R. andLemon, S. M. ( 2009) Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu. Rev. Pathol. 4, 399415.
  • 34
    Klopstock, N.,Katzenellenbogen, M.,Pappo, O.,Sklair-Levy, M.,Olam, D.,Mizrahi, L.,Potikha, T.,Galun, E., andGoldenberg, D. ( 2009) HCV tumor promoting effect is dependent on host genetic background. PLoS One 4, e5025.
  • 35
    Li, H. P.,Leu, Y. W., andChang, Y. S. ( 2005) Epigenetic changes in virus-associated human cancers. Cell Res. 15, 262271.
  • 36
    Fassati, A.,Gorlich, D.,Harrison, I.,Zaytseva, L., andMingot, J. M. ( 2003) Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. EMBO J. 22, 36753685.
  • 37
    Zaitseva, L.,Cherepanov, P.,Leyens, L.,Wilson, S. J.,Rasaiyaah, J., andFassati, A. ( 2009) HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. Retrovirology 6, 11.
  • 38
    Zaitseva, L.,Myers, R., andFassati, A. ( 2006) tRNAs promote nuclear import of HIV-1 intracellular reverse transcription complexes. PLoS Biol. 4, e332.
  • 39
    du Chene, I.,Basyuk, E.,Lin, Y. L.,Triboulet, R.,Knezevich, A.,Chable-Bessia, C.,Mettling, C.,Baillat, V.,Reynes, J.,Corbeau, P., Bertrand, E., Marcello, A., Emiliani, S., Kiernan, R., and Benkirane, M. ( 2007) Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424435.
  • 40
    Jordan, A.,Bisgrove, D., andVerdin, E. ( 2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 18681877.
  • 41
    Dieudonne, M.,Maiuri, P.,Biancotto, C.,Knezevich, A.,Kula, A.,Lusic, M., andMarcello, A. ( 2009) Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery. EMBO J. 28, 22312243.
  • 42
    Fuller, S. D.,Wilk, T.,Gowen, B. E.,Krausslich, H. G., andVogt, V. M. ( 1997) Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle. Curr. Biol. 7, 729738.
  • 43
    Wiegers, K.,Rutter, G.,Kottler, H.,Tessmer, U.,Hohenberg, H., andKrausslich, H. G. ( 1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72, 28462854.
  • 44
    Briggs, J. A.,Wilk, T.,Welker, R.,Krausslich, H. G., andFuller, S. D. ( 2003) Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22, 17071715.
  • 45
    Briggs, J. A.,Simon, M. N.,Gross, I.,Krausslich, H. G.,Fuller, S. D.,Vogt, V. M., andJohnson, M. C. ( 2004) The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11, 672675.
  • 46
    Briggs, J. A.,Riches, J. D.,Glass, B.,Bartonova, V.,Zanetti, G., andKrausslich, H. G. ( 2009) Structure and assembly of immature HIV. Proc. Natl. Acad. Sci. USA 106, 1109011095.
  • 47
    Garrus, J. E.,von Schwedler, U. K.,Pornillos, O. W.,Morham, S. G.,Zavitz, K. H.,Wang, H. E.,Wettstein, D. A.,Stray, K. M.,Cote, M.,Rich, R. L., Myszka, D. G., and Sundquist, W. I. ( 2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107, 5565.
  • 48
    Strack, B.,Calistri, A.,Craig, S.,Popova, E., andGottlinger, H. G. ( 2003) AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114, 689699.
  • 49
    VerPlank, L.,Bouamr, F.,LaGrassa, T. J.,Agresta, B.,Kikonyogo, A.,Leis, J., andCarter, C. A. ( 2001) Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci. USA 98, 77247729.
  • 50
    von Schwedler, U. K.,Stuchell, M.,Muller, B.,Ward, D. M.,Chung, H. Y.,Morita, E.,Wang, H. E.,Davis, T.,He, G. P.,Cimbora, D. M., Scott, A., Krausslich, H. G., Kaplan, J., Morham, S. G., and Sundquist, W. I. ( 2003) The protein network of HIV budding. Cell 114, 701713.
  • 51
    Carlson, L. A.,Briggs, J. A.,Glass, B.,Riches, J. D.,Simon, M. N.,Johnson, M. C.,Muller, B.,Grunewald, K., andKrausslich, H. G. ( 2008) Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe. 4, 592599.
  • 52
    Ivanchenko, S.,Godinez, W. J.,Lampe, M.,Krausslich, H. G.,Eils, R.,Rohr, K.,Brauchle, C.,Muller, B., andLamb, D. C. ( 2009) Dynamics of HIV-1 assembly and release. PLoS Pathog. 5, e1000652.
  • 53
    Neil, S. J.,Zang, T., andBieniasz, P. D. ( 2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425430.
  • 54
    Goffinet, C.,Allespach, I.,Homann, S.,Tervo, H. M.,Habermann, A.,Rupp, D.,Oberbremer, L.,Kern, C.,Tibroni, N.,Welsch, S., Krijnse-Locker, J., Bantin, G., Krausslich, H. G., Fackler, O. T., and Keppler, O. T. ( 2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 5, 285297.
  • 55
    Laffort, C.,Le Deist, F.,Favre, M.,Caillat-Zucman, S.,Radford-Weiss, I.,Debre, M.,Fraitag, S.,Blanche, S.,Cavazzana-Calvo, M.,de Saint Basile, G., de Villartay, J. P., Giliani, S., Orth, G., Casanova, J. L., Bodemer, C., and Fischer, A. ( 2004) Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 363, 20512054.
  • 56
    Melkert, P. W.,Hopman, E.,van den Brule, A. J.,Risse, E. K.,van Diest, P. J.,Bleker, O. P.,Helmerhorst, T.,Schipper, M. E.,Meijer, C. J., andWalboomers, J. M. ( 1993) Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int. J. Cancer 53, 919923.
  • 57
    Nees, M.,Geoghegan, J. M.,Hyman, T.,Frank, S.,Miller, L., andWoodworth, C. D. ( 2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75, 42834296.
  • 58
    Zhang, B.,Li, P.,Wang, E.,Brahmi, Z.,Dunn, K. W.,Blum, J. S., andRoman, A. ( 2003) The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 310, 100108.
  • 59
    Schmiedeskamp, M. R. andKockler, D. R. ( 2006) Human papillomavirus vaccines. Ann. Pharmacother. 40, 13441352.
  • 60
    Lee, C. W.,Senne, D. A., andSuarez, D. L. ( 2006) Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens. Clin. Vaccine Immunol. 13, 395402.
  • 61
    Capua, I. andAlexander, D. J. ( 2002) Avian influenza and human health. Acta Trop 83, 16.
  • 62
    Virelizier, J. L. ( 1975) Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J. Immunol. 115, 434439.
  • 63
    Virelizier, J. L. ( 2007) Rationale for treating human influenza infections by passive transfer of specific antibodies. Influenza Other Respir Viruses 1, 6164.
  • 64
    Fazekas de St, G. andWebster, R. G. ( 1966) Disquisitions on original antigenic sin. II. proof in lower creatures. J. Exp. Med. 124, 347361.
  • 65
    Fazekas de St, G. andWebster, R. G. ( 1966) Disquisitions of original antigenic Sin. I. evidence in man. J. Exp. Med. 124, 331345.
  • 66
    Welsh, R. M. andFujinami, R. S. ( 2007) Pathogenic epitopes, heterologous immunity and vaccine design. Nat. Rev. 5, 555563.
  • 67
    WHO ( 2008) Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Retrieved 31 October 2008.
  • 68
    Netland, J.,DeDiego, M. L.,Zhao, J.,Fett, C.,Alvarez, E.,Nieto-Torres, J. L.,Enjuanes, L., andPerlman, S. ( 2010) Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120128.
  • 69
    Lamirande, E. W.,DeDiego, M. L.,Roberts, A.,Jackson, J. P.,Alvarez, E.,Sheahan, T.,Shieh, W. J.,Zaki, S. R.,Baric, R.,Enjuanes, L., and Subbarao, K. ( 2008) A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 82, 77217724.
  • 70
    Siu, Y. L.,Teoh, K. T.,Lo, J.,Chan, C. M.,Kien, F.,Escriou, N.,Tsao, S. W.,Nicholls, J. M.,Altmeyer, R.,Peiris, J. S., Bruzzone, R., and Nal, B. ( 2008) The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J. Virol. 82, 1131811330.
  • 71
    Fauci, A. S. ( 2008) 25 years of HIV. Nature 453, 289290.
  • 72
    Das, S. R. andJameel, S. ( 2005) Biology of the HIV Nef protein. Indian J. Med. Res. 121, 315332.
  • 73
    Chaudhry, A.,Das, S. R.,Hussain, A.,Mayor, S.,George, A.,Bal, V.,Jameel, S., andRath, S. ( 2005) The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J. Immunol. 175, 45664574.
  • 74
    Hussain, A.,Wesley, C.,Khalid, M.,Chaudhry, A., andJameel, S. ( 2008) Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J. Virol. 82, 893902.
  • 75
    Mascola, J. R.,Stiegler, G.,VanCott, T. C.,Katinger, H.,Carpenter, C. B.,Hanson, C. E.,Beary, H.,Hayes, D.,Frankel, S. S.,Birx, D. L., and Lewis, M. G. ( 2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207210.
  • 76
    Brown, R. D. andHo, P. J. ( 2005) Multiple Myeloma: Methods and Protocols. Humana press Inc., Totowa, New Jersey.
  • 77
    Woodman, Z. andWilliamson, C. ( 2009) HIV molecular epidemiology: transmission and adaptation to human populations. Curr. Opin. HIV AIDS 4, 247252.
  • 78
    Sattentau, Q. ( 2008) Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. 6, 815826.
  • 79
    Barouch, D. H. ( 2008) Challenges in the development of an HIV-1 vaccine. Nature 455, 613619.
  • 80
    Barouch, D. H. andLetvin, N. L. ( 2002) Viral evolution and challenges in the development of HIV vaccines. Vaccine 20( Suppl 4), A66A68.
  • 81
    Guidotti, L. G.,Ando, K.,Hobbs, M. V.,Ishikawa, T.,Runkel, L.,Schreiber, R. D., andChisari, F. V. ( 1994) Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. USA 91, 37643768.
  • 82
    Verani, A. andLusso, P. ( 2002) Chemokines as natural HIV antagonists. Curr. Mol. Med. 2, 691702.
  • 83
    Ylisastigui, L.,Vizzavona, J.,Drakopoulou, E.,Paindavoine, P.,Calvo, C. F.,Parmentier, M.,Gluckman, J. C.,Vita, C., andBenjouad, A. ( 1998) Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. Aids 12, 977984.
  • 84
    Virelizier, J. L. ( 1999) Blocking HIV co-receptors by chemokines. Dev. Biol. Stand. 97, 105109.
  • 85
    Enjuanes, L.,Sola, I.,Almazan, F.,Ortego, J.,Izeta, A.,Gonzalez, J. M.,Alonso, S.,Sanchez, J. M.,Escors, D.,Calvo, E., Riquelme, C., and Sanchez, C. ( 2001) Coronavirus derived expression systems. J. Biotechnol. 88, 183204.
  • 86
    Zuniga, S.,Sola, I.,Cruz, J. L., andEnjuanes, L. ( 2009) Role of RNA chaperones in virus replication. Virus Res. 139, 253266.
  • 87
    Moreno, J. L.,Zuniga, S.,Enjuanes, L., andSola, I. ( 2008) Identification of a coronavirus transcription enhancer. J. Virol. 82, 38823893.
  • 88
    Ballesteros, M. L.,Sanchez, C. M., andEnjuanes, L. ( 1997) Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. Virology 227, 378388.
  • 89
    Kuo, L.,Godeke, G. J.,Raamsman, M. J.,Masters, P. S., andRottier, P. J. ( 2000) Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74, 13931406.
  • 90
    Lai, M. M. andCavanagh, D. ( 1997) The molecular biology of coronaviruses. Adv. Virus Res. 48, 1100.
  • 91
    Masters, P. S. ( 1999) Reverse genetics of the largest RNA viruses. Adv. Virus Res. 53, 245264.
  • 92
    Almazan, F.,Gonzalez, J. M.,Penzes, Z.,Izeta, A.,Calvo, E.,Plana-Duran, J., andEnjuanes, L. ( 2000) Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 97, 55165521.
  • 93
    Thiel, V.,Herold, J.,Schelle, B., andSiddell, S. G. ( 2001) Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J. Gen. Virol. 82, 12731281.
  • 94
    Fischer, F.,Stegen, C. F.,Koetzner, C. A., andMasters, P. S. ( 1997) Analysis of a recombinant mouse hepatitis virus expressing a foreign gene reveals a novel aspect of coronavirus transcription. J. Virol. 71, 51485160.
  • 95
    Sola, I.,Alonso, S.,Zuniga, S.,Balasch, M.,Plana-Duran, J., andEnjuanes, L. ( 2003) Engineering the transmissible gastroenteritis virus genome as an expression vector inducing lactogenic immunity. J. Virol. 77, 43574369.